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Abstract: Spatial control over the distribution and the aggregation of arginine-glycine-aspartate 
(RGD) peptides at the nanoscale signiﬁ  cantly affects cell responses. For example, nanoscale 
clustering of RGD peptides can induce integrins to cluster, thus triggering complete cell signal-
ing. Dendrimers have a unique, highly branched, nearly spherical and symmetrical structure 
with low polydispersity, nanoscale size, and high functionality. Therefore, dendrimers are a 
class of ideal scaffold for construction of nanoscale dendritic RGD clusters in which RGD 
loading degree and cluster size can be ﬁ  nely adjusted. This new type of nanoscale dendritic 
RGD cluster will aid us to better understand the impact of spatial arrangement of RGD on cel-
lular responses and to engineer RGD to trigger more favorable cellular responses. In this study, 
nanoscale dendritic RGD clusters were synthesized based on Starburst™ anionic G3.5 and 
cationic G4.0 polyamidoamine (PAMAM) dendrimers. The multiple terminal functional groups 
on the outermost layer of the dendrimer were coupled with RGD tripeptides. Biofunctionalized 
dendrimer structures were found to be highly dependent on the generation and the extent of 
peptide modiﬁ  cation (ie, number of peptides per PAMAM dendrimer). Fluorescein isothiocya-
nate (FITC)-conjugated PAMAM dendrimers were utilized to monitor cellular internalization 
of dendrimers by adherent ﬁ  broblasts. Anionic G3.5-based dendritic RGD clusters have been 
shown to have no negative effect on ﬁ  broblast viability and a concentration-dependent effect 
on lowering cell adhesion on tissue culture polystyrene (TCPS) as that of free RGD. A similar 
concentration-dependent effect in cell viability and adhesion was also observed for cationic 
G4.0-based dendritic RGD clusters at lower but not at high concentrations. The results imply 
that the synthesized nanoscale dendritic RGD clusters have great potential for tissue engineer-
ing and drug delivery applications.
Keywords: biofunctionalized dendrimer, confocal image, cytocompatibility, dendritic peptide, 
nanoclusters
Introduction
The arginine-glycine-aspartate (RGD) sequence present in many extracellular matrix 
(ECM) proteins such as collagen, ﬁ  bronectin, laminin, and vitronectin has been identi-
ﬁ  ed as a cell recognition motif to stimulate integrin-mediated cell adhesion (Ruoslahti 
and Pierschbacher 1987). Similar to the RGD sequence in ECM proteins, synthetic 
peptides containing the RGD sequence can promote cell adhesion after being immo-
bilized on a surface (Kao 1999). Therefore, polymers modiﬁ  ed with RGD as bioactive 
materials have been employed in a variety of tissue engineering and drug delivery 
applications. RGD spatial distribution patterns, as well as RGD concentration, affect 
cell adhesion, migration, and proliferation. It has been noticed that nanoscale clustering 
of RGD peptides plays an important role in regulating cellular responses. For example, 
RGD nanoclusters could better trigger cell adhesion by inducing integrin receptors 
to cluster in the cell membrane (Burridge et al 1988; Shaw et al 1990; Kornberg et al 
1991; Ginsberg et al 1992; Miyamoto, Akiyama, et al 1995; Miyamoto, Teramoto, 
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et al 1995). Maheshwari and colleagues (2000) demonstrated 
that cell motility could be adjusted by varying RGD ligand 
spatial arrangement at the nanoscale level and suggested that 
integrin clustering should be required to support cell motility. 
Irvine and colleagues (2001) employed comb copolymers of 
methyl methacrylate and poly (oxyethylene) methacrylate to 
construct nanoclusters of RGD peptides and achieved tunable 
control over cell adhesion (Irvine, Mayes, et al 2001; Irvine, 
Ruzette, et al 2001). 
Nanoclustering of RGD not only can serve as a unique 
matrix to elicit integrin-mediated cell responses but also 
has great potential for tissue engineering and drug delivery 
applications. Dendrimers are a new class of polymers playing 
an important role in the emerging ﬁ  led of nanobiotechnology 
(Bosman et al 1999; Yang and Kao 2006). Different from 
traditional polymers, dendrimers have a highly branched, 
three-dimensional, nanoscale architecture with very low 
polydispersity and high functionality (Tomalia et al 1985). 
Applications of dendrimers have been explored for drug 
delivery (Poxon et al 1996; Yang et al 2004; Yang and Lopina 
2005, 2006), gene transfer (Bielinska et al 2000; Eichman 
et al 2000; Luo et al 2002), imaging of biological systems 
(Kobayashi et al 2001; Bielinska et al 2002), etc. As den-
drimers have controllable structural components, including 
type and number of surface groups, surface charge, and scaf-
fold size, they are a class of ideal scaffold for construction 
of nanoscale dendritic RGD clusters in which RGD loading 
degree and cluster size can be ﬁ  nely adjusted. This new type 
of nanoscale dendritic RGD cluster with ﬁ  nely controllable 
structural components will help us to better understand the 
impact of spatial arrangement of RGD on cellular responses 
and to engineer RGD to trigger more favorable cellular 
responses, eg, rapid and stable cell adhesion. In this study, 
Starburst™ polyamidoamine (PAMAM) dendrimers were 
applied to construct nanoscale dendritic RGD clusters. The 
diameter of a PAMAM dendrimer molecule ranges from ap-
proximately 1.5 nm for G0 to 14.5 nm for G10. The primary 
amine or carboxylate surface groups on the outermost layer of 
the PAMAM dendrimer could be modiﬁ  ed to covalently link 
with RGD-containing peptides. Shukla and colleagues (2005) 
provided the ﬁ  rst dendrimer-RGD example by coupling bicy-
clic CDCRGDCFC (RGD-4C) to G5.0 PAMAM dendrimer 
for potential targeted cancer therapy. Nevertheless, the use of 
low generation dendrimers is preferred because low genera-
tion PAMAM dendrimers (below G5.0) have been shown to 
be potentially more biocompatible and less immunogenic 
than high generation PAMAM dendrimers. To demonstrate 
the feasibility of using low generation PAMAM dendrimers 
as RGD carrier, G3.5 and G4.0 PAMAM dendrimers and the 
tripeptide RGD sequence, ie, Arg-Gly-Asp, were used as 
the underlying materials to synthesize RGD clusters. G3.5 
and G4.0 PAMAM dendrimers contain 64 carboxylate and 
64 primary amine surface groups, respectively, to which 
the N-terminus of the RGD tripeptide was conjugated. As 
the RGD tripeptide has the simplest structure and the low-
est steric hindrance among the RGD-containing peptides, 
high RGD loading degrees could be achieved. To prove the 
robustness of the synthetic methods presented here, trigly-
cine (gly-gly-gly or GGG) was used as another tripeptide 
model and conjugated to G3.5 and G4.0 following the same 
synthetic strategies. A series of G3.5- and G4.0-based na-
noscale dendritic tripeptide clusters were synthesized and 
characterized with gel permeation chromatography (GPC) 
and proton nuclear magnetic resonance (1H-NMR) spectros-
copy. The cytotoxicity of dendrimers after being modiﬁ  ed 
with tripeptides was evaluated using ﬁ  broblasts. In addition, 
the effect of dendritic RGD peptides on ﬁ  broblast adhesion 
to tissue culture polystyrene (TCPS) was investigated and 
discussed. 
Materials and methods
Materials
Starburst™ G3.5 and G4.0 PAMAM dendrimers, triglycine 
(GGG), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC), N,N’-disuccinimidyl carbonate 
(DSC), N-hydroxysuccinimide (NHS), dimethylformamide 
(DMF), FITC, triethylamine (TEA), and sodium bicarbonate 
(NaHCO3) were purchased from Sigma-Aldrich (St. Louis, 
MO) and used as received. RGD was obtained from the 
Biotechnology Center of University of Wisconsin-Madison. 
The purity of RGD was over 95% as analyzed with high per-
formance liquid chromatography (HPLC) and matrix-assisted 
laser desorption/ionization time-of-ﬂ  ight (MALDI-TOF) 
A cell counting kit-8 (CCK-8) for cell viability tests was 
purchased from Dojindo (Kumamoto, Japan). BioCoat™ 
poly-D-lycine coverslip bottom-dishes were purchased from 
BD Biosciences (San Jose, CA). Milli-Q deionized water was 
used throughout the studies.
Characterization 
1H-NMR spectra were acquired and processed on a 400 
MHz Varian UNITYINOVA spectrometer (Palo Alto, CA). 
The internal reference standard was tetramethylsilane International Journal of Nanomedicine 2007:2(1) 91
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(TMS). Deuterium oxide (D2O, 99.9%) was obtained from 
Cambridge Isotope Laboratories (Andover, MA). Each 
sample was dissolved in D2O, ﬁ  ltered, and degassed before 
measurement. The chemical shift for D2O is 4.8 ppm. 
GPC analyses were performed on a Waters Breeze™ 
GPC system (Milford, MA). The GPC system contained 
three Ultrahydrogel™ columns – Ultrahydrogel™ Lin-
ear, Ultrahydrogel™ 1000, and Ultrahydrogel™ 250 
– to cover the molecular weight ranging from 1 × 103 to 
7 × 106 daltons. The mobile phase was composed of 80 
wt% 0.1 M NaNO3 and 20 wt% acetonitrile. The eluent 
with a flow rate at 0.5 mL/min was monitored by a Waters 
2414 refractive index detector.
Synthesis of dendritic tripeptide 
nanoclusters 
G3.5-based dendritic peptides
Before being coupled with RGD, the carboxylate surface 
groups of G3.5 were converted to active NHS esters, fol-
lowing the method described previously (Yang and Lopina 
2003, 2005) (Scheme 1). Brieﬂ  y, 30 mg of dry G3.5 was 
obtained after removal of methanol from the storage solution 
using rotary evaporation. The desiccated G3.5 sample was 
then dissolved in 2 mL of deionized water and acidiﬁ  ed to 
pH 3 or below with a few drops of 1 N hydrochloric acid. 
The acidiﬁ  ed G3.5 was evaporated to dryness under vacuum, 
and then redissolved in a mixture solution containing 0.8 
mL of DMF and 0.2 mL of deionized water. To the G3.5 
solution were added 22.7 mg of NHS and 39.4 mg of EDC. 
NHS-activated G3.5 was then produced after 14 h reaction. 
Following a vacuum drying step, the NHS-activated G3.5 
continued to react with RGD in 2 mL of pH 8.5 sodium 
bicarbonate solution for 2 h where the feeding molar ratio of 
RGD/G3.5 was 64:1. After extensive dialysis and subsequent 
lyophilization, RGD-G3.5 was obtained and characterized 
with GPC and 1H-NMR. A series of GGG-G3.5 were synthe-
sized by varying the feeding molar ratio of GGG/G3.5 (16:1, 
32:1, and 64:1) following the same synthesis procedures as 
described above.
G4.0-based dendritic peptides
Similar to the synthesis of G3.5-based dendritic peptides, 
the primary amine surface groups of G4.0 were converted 
to active NHS esters first (Scheme 2). Briefly, 1.8 mL 
of DMF containing 30 mg of G4.0 was dropwise added 
to a DMF solution (2 mL) containing 35 mg of DSC. 
Afterwards, slow addition of TEA to the solution was per-
formed and then followed by an overnight reaction with 
stirring. The supernatant containing NHS-activated G4.0 
was collected after centrifugation. The NHS-activated 
G4.0 was then precipitated out of cold ether and vacuum 
dried. A 2-h coupling reaction between NHS-G4.0 and 
RGD was carried out in a pH 8.5 biocarbonate buffer 
solution where the feeding molar ratio of RGD/G4.0 
was 64:1. The resulting RGD-G4.0 was purified by using 
extensive dialysis and then characterized with GPC and 
1H-NMR. A series of GGG-G4.0 with various feeding 
ratio of GGG/G4.0 (16:1, 32:1, and 64:1) were obtained 
using the above synthesis procedures.
Cytotoxicity assay
The potential cytotoxic effect of the synthesized dendritic 
tripeptides was investigated in vitro using ﬁ  broblasts. Clo-
netics™ dermal ﬁ  broblast systems were purchased from 
Cambrex (Walkersville, MD). The systems contained normal 
human dermal ﬁ  broblasts and cell growth medium, ie, Clonet-
ics FGM® BulletKit. The BulletKit contained ﬁ  broblast cell 
basal medium and growth supplements: hFGF-B, insulin, and 
GA-1000. Cell culture of ﬁ  broblasts followed the protocols 
provided by the supplier. 
The wells of 96-well plates were plated with 2000 
ﬁ  broblasts in 100 μL of growth medium. Fibroblasts were 
then allowed to adhere and grow for two days at 37 °C in 
an atmosphere of 5% CO2 and 95% relative humidity. The 
cells were then exposed to 0.2, 2, or 20 μM of G3.5, G4.0, 
or dendritic triglycine in medium for 12, 24, or 96 h. At the 
end of each predetermined time point, the treated cells were 
assayed using a CCK-8 kit, where 10 μl of CCK-8 solution 
was added to 100 μL of fresh growth medium. Two hours 
later, the optical absorbance of medium in each well was read 
 
PAMAM COOH
m m m
NH2-RGD
NaHCO3/pH 8.5
EDC/NHS  PAMAM PAMAM CONHRGD CONHS
Scheme 1 Synthesis of RGD-G3.5 conjugates. 
Abbreviation: RGD, arginine-glycine-aspartate..International Journal of Nanomedicine 2007:2(1) 92
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on an EL × 800™ absorbance microplate reader (Bio-TEK) 
at a test wavelength of 450 nm and a reference wavelength 
of 630 nm. Cell viability was calculated as follows:
  Cell viability (%) = 
AA
AA
test blank
control blank
−
−
×100 
where Atest is absorbance of a well with cells, CCK-8 solu-
tion and polymer solution; Ablank is absorbance of a well 
with medium and CCK-8 solution, without cells; Acontrol is 
absorbance of a well with cells and CCK-8 solution, without 
polymer solution. Morphology of ﬁ  broblasts was observed 
on an Olympus TE300 phase-contrast microscope at a total 
100 × magniﬁ  cation. The cell viability data were expressed 
as means ± SEM (n = 4). In order to take account of the 
potential cytotoxic effect of RGD-dendrimer on cell adhe-
sion, ﬁ  broblasts were exposed to 0.77, 77, or 770 μM of free 
RGD, RGD-G3.5 or RGD-4.0 for 2 h. The cell viability at 2, 
24, and 96 h post treatment was determined using the same 
method as described above.
Cellular entry of FITC-labeled G4.0 
PAMAM dendrimer 
To label G4.0 PAMAM dendrimer with FITC, the cor-
responding amount of FITC (dendrimer/FITC molar 
ratio=1:1) was dissolved in acetone to give a solution of 
concentration <5 mg/ml and then added to the pH 7.4 PBS so-
lution where G4.0 was dissolved previously. The FITC/G4.0 
was thoroughly mixed overnight at room temperature with 
stirring. The FITC-labeled G4.0 solution was then dialyzed 
against deionized water to remove the unconjugated FITC. 
The resulting FITC-G4.0 conjugates were subsequently 
lyophilized and stored at 4 °C when not in use. Fibroblasts 
were plated on the poly-D-lysine coated glass bottom culture 
dishes at the seeding density of 1 × 104 cells/mL. Two days 
later, FITC-G4.0 conjugates were added to the cell medium 
at the ﬁ  nal concentration of 0.422 mg/mL and allowed to 
interact with ﬁ  broblasts for 15 min, 1 h, and 2 h, respectively. 
By the end of each predetermined time point, the old growth 
medium was removed and the cells were rinsed three times 
with fresh growth medium. The cells were then imaged with 
a Radiance 2100-multiphoton/confocal imaging (Bio-Rad) 
system. The cells were visualized vertically at different sec-
tions with 2 μm thickness between two neighbor sections. 
The overall magniﬁ  cation was 400 ×.
Fibroblast adhesion to TCPS in dendritic 
peptide suspension 
Freshly isolated ﬁ  broblasts at 104 cells/mL in 100 μL of 
serum-free medium were transferred to each well of a TCPS 
96-well culture plate and exposed to 0, 0.77, 77, or 770 μM 
of free RGD, RGD-G3.5, or RGD-G4.0 for 2 h. After the 
unattached ﬁ  broblasts were aspirated out, adherent ﬁ  bro-
blasts at 2 h and 96 h post treatment were quantiﬁ  ed based 
on measurements from three randomly selected ﬁ  elds using 
an Olympus TE300 phase-contrast microscope. 
Statistical analysis
The data were expressed as means ± SEM. Statistical 
evaluation of the data was performed by analysis of variance 
(ANOVA) followed by Student-Newman-Keuls test for pair-
wise comparison of subgroups. Differences among means were 
considered statistically signiﬁ  cant at a p value of ≤0.05.
Results and discussion
Cytotoxicity of dendritic peptides
Nanoscale dendritic clusters of RGD and GGG tripeptides 
were synthesized and analyzed in a similar way owing to 
the similarity in their chemical structures. As the C-terminus 
of RGD is essential for keeping RGD active in mediating 
integrin-based cell adhesion, the N-terminus of the RGD 
tripeptide was modiﬁ  ed to link with the ending groups on 
the dendrimer surface (Hersel et al 2003). NHS-activated 
esters can readily react with the primary amine group pres-
ent at the N-terminus of the peptide. To achieve high peptide 
loading degree, dendrimer surface groups were converted 
PAMAM PAMAM PAMAM RGD
H
N
H
N
O m
H
N
N
O
O
O
O DSC
TEA m
m
NH2
NH2-RGD
NaHCO3/pH 8.5
Scheme 2 Synthesis of RGD-G4.0 conjugates.
Abbreviation: RGD, arginine-glycine-aspartate.International Journal of Nanomedicine 2007:2(1) 93
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to active NHS-activated esters prior to the coupling reac-
tion. NHS and DSC were used to activate carboxylate and 
primary amine surface groups, respectively. The resulting 
dendritic tripeptides were then characterized with GPC and 
1H-NMR. According to the GPC data, dendritic clusters of 
tripeptides showed distinct peak domains based on elution 
time as peptide loading degree varied. 1H-NMR spectroscopy 
was applied to further analyze the structure of the tripeptide-
dendrimer conjugates. For example, the 1H-NMR spectrum 
of 16GGG-G3.5 (Figure 1) shows the presence of the proton 
peaks of both GGG (three methylene peaks between 3.75 
ppm and 4.00 ppm) and G3.5 (multiple methylene protons 
between 2.5 ppm and 3.6 ppm), indicating the success of 
coupling of GGG to G3.5. Peptide loading degree depends on 
the feeding ratio of peptide/dendrimer, reaction conditions, 
and coupling efﬁ  ciency (Yang et al 2004).The peptide load-
ing degree was estimated between 80%–90% according to 
the 1H-NMR spectrum. High peptide loading degrees were 
achieved because of activation of the surface groups by NHS 
and the negligible steric hindrance of RGD and GGG. 
It has been well recognized that the cytotoxicity of den-
drimers is a function of surface charge, size, and concentration 
(Jevprasesphant et al 2003). The interaction between positively 
charged dendrimers and negatively charged cell surfaces is 
believed to be the cause of the cytotoxicity of cationic PAMAM 
dendrimers that contain primary amine surface groups. Surface 
modiﬁ  cation has proved to be an effective way to minimize the 
cytotoxicity of dendrimers by decreasing the overall positive 
surface charge of the dendrimer (Roberts et al 1996; Malik et al 
2000; Jevprasesphant et al 2003). The effect of tripeptide con-
jugation on the cytotoxicity of the dendrimer was investigated 
using ﬁ  broblasts. The cytotoxicity assay (CCK-8 kit) measured 
the activity of most of the dehydrogenases in a ﬁ  broblast cell. As 
shown in Figure 2A, G3.5 PAMAM dendrimer did not induce 
a cytotoxic response in ﬁ  broblasts at 0.2, 2, or 20 μM for up 
to 96 h. Furthermore, GGG-modiﬁ  ed G3.5 PAMAM did not 
induce cytotoxicity to ﬁ  broblasts (Figure 2B, C, and D). All data 
points were statistically comparable. The cytotoxicity of G4.0 
PAMAM dendrimer was concentration and time dependent. 
G4.0 PAMAM dendrimer did not cause ﬁ  broblast viability 
loss at 0.2 μM up to 96 h; however, G4.0 PAMAM dendrimer 
signiﬁ  cantly reduced the cell viability as the concentration and 
incubation time increased. There were no viable ﬁ  broblasts after 
96 h-incubation when the concentration of G4.0 was 2 μM or 
20 μM (Figure 3A). Coupling of GGG to the dendrimer surface 
signiﬁ  cantly reduced the cytotoxicity of G4.0, extending the 
toxicity tolerance of ﬁ  broblasts to the triglycine-modiﬁ  ed G4.0 
PAMAM dendrimers from 0.2 μM to 2 μM within 96 h (Figures 
3B, 3C, and 3D). Among triglycine-loaded G4.0 PAMAM 
dendrimers, 64GGG-G4.0 showed remarkably high cytocom-
patibility even at 20 μM up to 12 h, which was comparable to 
that at 0.2 and 2 μM. In addition, 64GGG-G4.0 appeared to have 
methylene of G3.5 PAMAM
methylene of triglycine
1.0
D20
ppm 4.0 3.0 2.0
Figure 1 1H-NMR spectrum of 16GGG-G3.5.
Abbreviations: 1H-NMR, proton nuclear magnetic resonance.International Journal of Nanomedicine 2007:2(1) 94
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had little effect on the ﬁ  broblast cell morphology compared with 
the control cells at 12 h.
Through the modiﬁ  cation with GGG, the cytotoxicity of 
G4.0 PAMAM dendrimer was reduced signiﬁ  cantly. How-
ever, the cytotoxicity reduction of G4.0 depended on peptide 
loading degree, and the toxicity tolerance of ﬁ  broblasts to 
peptide-loaded G4.0 was time and concentration dependent. 
Cell morphology was consistent with cell viability changes. 
The cells without cytotoxic effect spread over; in contrast, the 
cells with cytotoxic effect became rounded and started to die. 
As shown in Figure 4, at 20 μM, 64GGG-G4.0 has much less 
cytotoxic effect on cell morphology than 16GGG-G4.0 and 
32GGG-G4.0 up to 24 h. The results indicated that the conjuga-
tion of tripeptides to the dendrimer surface resulted in reduction 
of cytotoxicity of cationic G4.0 PAMAM dendrimer. 
Internalization of FITC-labeled cationic 
G4.0 by ﬁ  broblasts 
The interaction between G4.0 PAMAM dendrimer with ﬁ  -
broblasts was visualized by coupling FITC to the dendrimer 
surface. The confocal images have shown that the FITC-
labeled G4.0 could enter inside the ﬁ  broblast within 15 min 
(Figure 5A-D). The staining at 15 min is punctuated, sug-
gesting that dendrimers were endocytosed following the en-
dosome/lysosome pathway. The strong ﬂ  uorescence signals 
were found throughout the cytoplasm at the later time points, 
indicating a major accumulation place of FITC-labeled G4.0 
PAMAM dendrimer inside the ﬁ  broblast. This result was 
similar to the dendrimer localization within human lung 
carcinoma epithelial cell line A549 (Khandare et al 2005) 
and Caco-2 cells (Jevprasesphant et al 2004). In addition, 
the visualization of ﬂ  uorescence at horizontal layers (from 
A to D) conﬁ  rmed that FITC-G4.0 did enter the cell instead 
of attaching to the cell membrane. As shown in Figure 5, 
the very strong ﬂ  uorescence signals at the edge of the cell 
suggest that a certain fraction of FITC-G4.0 molecules may 
still bind to the cell membrane due to the electrostatic inter-
actions during the observation. The binding of ﬂ  uorescein-
labeled PAMAM dendrimers to the surface of individual 
ﬁ  broblast cells has been conﬁ  rmed and quantiﬁ  ed using 
Figure 2 Viability of ﬁ  broblasts incubated with G3.5 (A), 16GGG-G3.5 (B), 32GGG-G3.5 (C), and 64GGG-G3.5 (D).
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confocal ﬂ  uorescence microscopy in a previous work done 
by Lai and colleagues (2002). The internalized FITC-G4.0 
PAMAM dendrimers remained stably and intracellularly 
over 2 hours (Figure 5F). The nonspecific intracellular 
localization of FITC-G4.0 may cause many organelles to 
be involved with G4.0 PAMAM dendrimer. Particularly, 
the cell viability measured in this study was based on the 
cell’s dehydrogenase activity. Mitochondria play an impor-
tant role in regulating cell death and many dehydrogenases 
are found inside the mitochondrion. We hypothesized that 
the loss of cell viability may be due to the interference of 
the internalized G4.0 PAMAM dendrimers with mitochon-
dria. However, more biological assays and measurements 
are needed to verify this hypothesis and beyond the focus 
of this study. Nevertheless, quick entry into cell membrane 
and intracellular stabilization has made cationic PAMAM 
dendrimers like G4.0 have strong cytotoxic effect on cell 
viability. It must be noted that these phenomena are reﬂ  ec-
tive of the property of FITC-conjugated PAMAM and not 
PAMAM-only. The inﬂ  uence of FITC molecules in cellular 
uptake should also be considered.
Fibroblast adhesion to TCPS in dendritic 
peptide suspension
TCPS is a commonly used substrate to support cell attach-
ment, spreading, and proliferation. To evaluate the bioavail-
ability of RGD after being conjugated to the dendrimer, 
ﬁ  broblast adhesion to TCPS in the dendritic RGD suspension 
was quantiﬁ  ed in terms of adherent cell density. Fibroblasts 
were treated with free RGD, RGD-3.5, and RGD-4.0 of 
varying concentrations in a serum-free medium for 2 h. After 
the unattached cells were gently rinsed out, the adherent 
ﬁ  broblasts on the TCPS were counted at 2 h and 96 h post 
treatment. By varying the concentration of free RGD in a 
wide range from 0.77 μM to 770 μM, free RGD inhibited 
cell adhesion on TCPS in a concentration-dependent man-
ner. At 0.77 μM, the presence of free peptides had little 
effect on cell adhesion compared with the control cells. So 
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Figure 3 Viability of ﬁ  broblasts incubated with G4.0 (A), 16GGG-G4.0 (B), 32GGG-G4.0 (C), and 64GGG-G4.0 (D).International Journal of Nanomedicine 2007:2(1) 96
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did RGD-3.5 and RGD-G4.0 at 0.77 μM. But, free RGD 
peptides decreased the number of adherent ﬁ  broblasts as the 
concentration increased (Figure 6). At 770 μM, RGD signiﬁ  -
cantly inhibited cell adhesion. The cell density, after RGD 
treatment at 770 μM for 2 h, dropped 70%–75% compared 
with the control. To compare the dendritic RGD peptides 
with the RGD tripeptide, we chose to make the concentra-
tions of dendritic peptides equivalent to those of free RGD 
peptides. We found the similar decrease in cell density as 
the concentration of dendritic peptides increased. The con-
centrations at 77 μM and 770 μM were much higher than 
the range we chose for the cytotoxicity study. Cytotoxicity 
A1 B1 C1
C2
C3 B3
B2 A2
A3
C4 B4 A4
Figure 4 Morphology of ﬁ  broblasts incubated with 20 μM of GGG-G4.0 conjugates (A, 12 h; B, 24 h; C, 96 h; 1, control; 2, 16GGG-G4.0; 3, 32GGG-G4.0; 4, 64GGG-G4.0).International Journal of Nanomedicine 2007:2(1) 97
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induced by such high concentration doses may also cause 
cell adhesion inhibition. In order to consider the cytotoxic 
effect of dendritic peptides on ﬁ  broblast adhesion, cell vi-
ability at 2, 24, and 96 h post 2-h-treatment with dendritic 
peptides was measured using the CCK-8 kit. According to 
the cytotoxicity assay (Figure 7), RGD-G4.0 at 770 μM was 
most toxic, causing permanent damage to ﬁ  broblasts at 24 h 
and 96 h, which, however, was not obvious at 2 h. The cy-
totoxicity of RGD-G4.0 at 77 μM was mild, causing a 20% 
drop of cell viability. The decrease in adherent cell density 
at the presence of RGD-G4.0 was mainly due to RGD-G4.0 
cytotoxicity. Like free RGD, RGD-G3.5 was not toxic, and 
showed a similar ability in cell adhesion inhibition to free 
RGD at 2 h. In this ﬁ  broblast adhesion study, those rounded 
cells were not counted as adherent cells although they were 
attached to the surface at 2 h. We suspected that those ini-
tially rounded cells started to spread and proliferate within 
96 hours as there was no signiﬁ  cant difference in adherent 
cell density of those cells treated with free RGD, RGD-G3.5, 
or RGD-G4.0 when measured at 96 h.
The inhibited ﬁ  broblast adhesion to TCPS in the pres-
ence of RGD suspension was not well understood. However, 
as hydrophilic and ionic interaction between ﬁ  broblast and 
TCPS is essential for cell adhesion on TCPS, we believe that 
the binding of RGD clusters to the ﬁ  broblast via integrin 
receptors may lead to the decreased hydrophilic and ionic 
interaction between ﬁ  broblast and TCPS, thus disrupting 
cell adhesion. In addition, ﬁ  broblasts can secret adhesive 
ﬁ  bronectin proteins in a serum-free medium (Grinnell and 
Feld 1979). Sufﬁ  cient amounts of secreted ﬁ  bronectin assist 
ﬁ  broblasts with attachment and spreading on the substrate 
(Grinnell and Feld 1979). It is envisioned that once the RGD 
clusters were introduced into the ﬁ  broblast suspension, the 
clustered RGD peptides would compete with the secreted 
ﬁ  bronectin proteins in integrin-binding, resulting in com-
petitive inhibition of integrin-mediated ﬁ  broblast adhesion 
to the TCPS substrate.
This work shows that anionic G3.5 PAMAM dendrimer 
can be used to construct dendritic RGD clusters with a similar 
ability in cell adhesion inhibition to free RGD. Once RGD 
peptides are clustered on the dendrimer surface, the number 
of available RGD tripeptides from the dendritic cluster for 
binding with cell membrane receptors may be reduced since 
only a portion of RGD peptides on the dendrimer surface can 
interact with the cell as illustrated in Figure 8. Therefore, 
high peptide loading degree of dendritic RGD clusters will 
not be necessary if the conjugated RGD tripeptides are not 
fully utilized for cell membrane binding. The marginal use 
of the conjugated RGD tripeptides on the dendrimer surface 
can be used to explain why the dendritic RGD clusters only 
showed comparable cell adhesion inhibition as opposed to 
free RGD in this study. The preliminary results have rendered 
the possibility of using nanoscale dendritic RGD clusters 
for drug delivery and tissue engineering applications. For 
example, a few RGD-containing peptides have been shown 
to bind to speciﬁ  c cell lines for tumor treatment and gene 
therapy (Colin et al 1998; Harbottle et al 1998; Aoki et al 
2001). Dendritic RGD clusters containing abundant surface 
groups can be further modiﬁ  ed with therapeutic entities to 
build dendrimer-based targeted drug delivery systems. Such 
targeted drug delivery systems will recognize cells contain-
ing integrin-receptors and exert therapeutic effects locally. 
Moreover, dendritic RGD clusters can be covalently grafted 
to the substrate to promote cell adhesion as free RGD-bound 
surface. Further functionalization of dendritic RGD clusters 
     
A B
C D
F E
Figure 5 Confocal images of ﬁ  broblasts at different horizontal sections at 15 min 
(from A (apical) to D (basal), 2 μm thickness between two neighbor sections), 1 h 
(E), and 2 h (F) (magniﬁ  cation 400×).International Journal of Nanomedicine 2007:2(1) 98
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on the substrate will create unparalleled opportunities to 
develop highly adaptable and multifunctional substrates for 
tissue engineering applications. Future study will be focused 
on the impact of structural variation of dendritic RGD clusters 
on cellular responses and exploration of their potential drug 
delivery and tissue engineering applications.
Conclusions
Nanoscale dendritic RGD clusters were synthesized based 
on anionic G3.5 and cationic G4.0 PAMAM dendrimers. 
Biofunctionalized dendrimer structures were found highly 
dependent on the generation and the extent of peptide 
modification (ie, number of peptide per PAMAM). An-
ionic G3.5-based dendritic RGD clusters in suspension 
have shown no negative effect on fibroblast viability 
and a concentration-dependent effect on lowering cell 
adhesion to TCPS as that of free RGD. A concentration-
dependent effect on cell viability and adhesion was also 
observed for cationic G4.0-based RGD at lower but not 
at high concentrations.
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Figure 6 Adherent ﬁ  broblast density at 2 h (A) and 96 h (B) after 2 h-treatment 
with RGD peptides.
Abbreviation: RGD, arginine-glycine-aspartate.
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Figure 7 Viability of ﬁ  broblasts at 2 h (A), 24 h (B), and 96 h (C) after 2 h-treat-
ment with RGD peptides.
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Figure 8 Schematic illustration of a nanoscale dendritic RGD cluster binding with 
integrin receptors.
Abbreviation: RGD, arginine-glycine-aspartate